Amplia Therapeutics Ltd. (AU:ATX) has released an update.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Amplia Therapeutics Ltd. has successfully completed the allotment of over 67 million shares at $0.115 each, raising $13 million through an institutional placement. This capital raise bolsters Amplia’s financial position as it continues its research and trials, particularly in developing its promising cancer drug, narmafotinib. The company’s strategic focus on FAK inhibitors positions it attractively in the evolving cancer treatment market.
For further insights into AU:ATX stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue